AIM ImmunoTech
13 hedge funds and large institutions have $1.53M invested in AIM ImmunoTech in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
11% more capital invested
Capital invested by funds: $1.38M → $1.53M (+$157K)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$519K |
| 2 |
Bank of New York Mellon
New York
|
+$7.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$129K |
| 2 |
Renaissance Technologies
New York
|
-$34.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22K |
| 4 |
BlackRock
New York
|
-$17.3K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $472K | -$129K | -52 | -20% |
|
|
AFM
2
Anson Funds Management
Dallas,
Texas
| $462K | +$519K | +210 | New |
|
|
3
BlackRock
New York
| $230K | -$17.3K | -7 | -6% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $227K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $37K | – | – | – |
|
|
6
Renaissance Technologies
New York
| $36K | -$34.6K | -14 | -47% |
|
7
Creative Planning
Overland Park,
Kansas
| $20K | – | – | – |
|
8
Northern Trust
Chicago,
Illinois
| $16K | – | – | – |
|
|
9
Bank of New York Mellon
New York
| $13K | +$7.42K | +3 | +100% |
|
|
OAM
10
Occidental Asset Management
Burlingame,
California
| $8K | – | – | – |
|
|
GC
11
Guggenheim Capital
Chicago,
Illinois
| $6K | – | – | – |
|
|
WPW
12
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $5K | – | – | – |
|
13
UBS Group
Zurich,
Switzerland
| $1K | -$2.47K | -1 | -50% |
|
14
Morgan Stanley
New York
| $1K | – | – | – |
|
|
15
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$22K | -9 | Closed |
|
|
PAM
16
Panagora Asset Management
Boston,
Massachusetts
| – | -$14K | -6 | Closed |
|
AIM Hedge Fund Activity: Q2 2017 in Review
13 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2017, worth a combined $1.53M — up 11% from $1.38M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AIM and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $519K. The largest seller was Sabby Management, cutting an estimated $129K.
- 13 institutional investors held AIM ImmunoTech (AIM) as of Q2 2017, down from 14 in Q1 2017.
- Funds reported $1.53M of AIM ImmunoTech stock for Q2 2017, up 11% quarter-over-quarter.
- 1 fund opened new AIM ImmunoTech positions in Q2 2017 and 2 closed out, a net change of -1 holder.
- The largest AIM ImmunoTech buyer in Q2 2017 was Anson Funds Management, an estimated $519K added.
- The largest AIM ImmunoTech seller in Q2 2017 was Sabby Management, an estimated $129K sold.
Based on aggregated 13F filings for Q2 2017.